Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin.
10.4093/dmj.2016.40.3.230
- Author:
Jong Ho KIM
1
;
Sang Soo KIM
;
Hong Sun BAEK
;
In Kyu LEE
;
Dong Jin CHUNG
;
Ho Sang SOHN
;
Hak Yeon BAE
;
Mi Kyung KIM
;
Jeong Hyun PARK
;
Young Sik CHOI
;
Young Il KIM
;
Jong Ryeal HAHM
;
Chang Won LEE
;
Sung Rae JO
;
Mi Kyung PARK
;
Kwang Jae LEE
;
In Joo KIM
Author Information
1. Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea. injkim@pusan.ac.kr
- Publication Type:Multicenter Study ; Original Article
- Keywords:
Dipeptidyl peptidase 4 inhibitor;
Metformin;
Thiazolidinediones
- MeSH:
Blood Glucose;
Body Weight;
Cholesterol;
Hemoglobin A, Glycosylated;
Humans;
Lipoproteins;
Metformin*;
Thiazolidinediones
- From:Diabetes & Metabolism Journal
2016;40(3):230-239
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: We compared the efficacies of vildagliptin (50 mg twice daily) relative to pioglitazone (15 mg once daily) as an add-on treatment to metformin for reducing glycosylated hemoglobin (HbA1c) levels in Korean patients with type 2 diabetes. METHODS: The present study was a multicenter, randomized, active-controlled investigation comparing the effects of vildagliptin and pioglitazone in Korean patients receiving a stable dose of metformin but exhibiting inadequate glycemic control. Each patient underwent a 16-week treatment period with either vildagliptin or pioglitazone as an add-on treatment to metformin. RESULTS: The mean changes in HbA1c levels from baseline were -0.94% in the vildagliptin group and -0.6% in the pioglitazone group and the difference between the treatments was below the non-inferiority margin of 0.3%. The mean changes in postprandial plasma glucose (PPG) levels were -60.2 mg/dL in the vildagliptin group and -38.2 mg/dL in the pioglitazone group and these values significantly differed (P=0.040). There were significant decreases in the levels of total, low density lipoprotein, high density lipoprotein (HDL), and non-HDL cholesterol in the vildagliptin group but increases in the pioglitazone group. The mean change in body weight was -0.07 kg in the vildagliptin group and 0.69 kg in the pioglitazone group, which were also significantly different (P=0.002). CONCLUSION: As an add-on to metformin, the efficacy of vildagliptin for the improvement of glycemic control is not inferior to that of pioglitazone in Korean patients with type 2 diabetes. In addition, add-on treatment with vildagliptin had beneficial effects on PPG levels, lipid profiles, and body weight compared to pioglitazone.
